In its first clinical trial in patients with a hard-to-treat form of uterine cancer, a targeted drug that subjects tumor cells to staggering levels of DNA damage caused tumors to shrink in nearly one-third of patients, investigators at Dana-Farber Cancer Institute report.
A team of investigators from Winship Cancer Institute of Emory University has shown outstanding long term survival results for multiple myeloma patients from a 3-drug induction regimen in a study published in the Journal of Clinical Oncology.
Cue Biopharma Inc. and Merck are evaluating the combination of Cue Biopharma's investigational product candidate CUE-101, a first-in-class biologic, with Merck's Keytruda in patients with advanced head and neck cancer.
Elicio Therapeutics and NCI are working together to characterize T cell responses to ELI-002 in animals.
Juul sales recovered within weeks following a dip after the company withdrew some flavored products from stores, eventually surpassing sales from before the change, according to a study by American Cancer Society researchers in the American Journal of Public Health.
New preclinical research from a team at Roswell Park Comprehensive Cancer Center suggests a strategy for significantly increasing both the local and distant, or “abscopal,” effects of radiation, according to a study.
The phase III confirmatory ASCENT study—designed to validate the promising safety and efficacy data of sacituzumab govitecan observed in a phase II study of heavily pretreated patients with metastatic triple negative breast cancer—will be halted due to compelling evidence of efficacy.
Following physical activity guidelines from the U.S. Department of Health and Human Services can improve clinical outcomes for patients with high-risk breast cancer, according to a study published in the Journal of the National Cancer Institute.
A drug combination discovered by the UT Southwestern Simmons Cancer Center may extend the effectiveness of a lung cancer treatment and make it available to many more patients.
The phase III KEYNOTE-177 trial evaluating first-line treatment of Keytruda in patients with microsatellite instability-high or mismatch repair deficient unresectable or metastatic colorectal cancer met one of its dual primary endpoints of progression-free survival.
